molecules of the month


oral, dual-selective αvβ6-αvβ1 integrin inhibitor

Ph. II for IPF and PSC

related to reported integrin inhibitors

Press release, January 22, 2023

Pliant Therapeutics, South San Francisco, CA

bexotegrast chemical structure oral, dual-selective αvβ6/αvβ1 integrin inhibitor - Pliant Therapeutics, South San Francisco, CA
8 mins read

A surprisingly safe and possibly efficacious dual-selective αvβ6-αvβ1 inhibitor, providing therapeutic entry to the notoriously challenging TGF-β pathway. Integrins are cell adhesion proteins that help cells bind to the extracellular matrix and have a range of signaling functions. The arginyl-glycinyl-aspartic acid (RGD) subfamily of αv integrins have been studied for decades in a variety of indications including cancer and idiopathic pulmonary fibrosis (IPF). Targeting αv integrins has been attractive yet challenging as they are upstream of transforming growth factor-β (TGF-β), and both small molecule and antibody-based integrin inhibitors have demonstrated preclinical toxicities in non-human primates, including cardiovascular toxicities and hyperplasia. TGF-β is an extensively studied target with established roles across therapeutic areas, but the systemic blockade of its pathway comes…

request a trial

Drug Hunter is commited to helping industry innovators make informed decisions. Premium members have access to our library of the latest stories in science, written by scientists.

Request a trial to access insights powering the pros in our industry.

already a member? log in: